Related Experiment Video
Updated: Oct 6, 2025

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
Tong Liu1, Inci Dogan2, Michael Rothe2
1Experimental and Clinical Research Center (ECRC), Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, 13125 Berlin, Germany.
Abstract:
Factors causing the increased cardiovascular morbidity and mortality in hemodialysis (HD) patients are largely unknown. Oxylipins are a superclass of lipid mediators with potent bioactivities produced from oxygenation of polyunsaturated fatty acids. We previously assessed the impact of HD on oxylipins in arterial blood plasma and found that HD increases several oxylipins. To study the phenomenon further, we now evaluated the differences in arterial and venous blood oxylipins from patients undergoing HD. We collected arterial and venous blood samples in upper extremities from 12 end-stage renal disease (ESRD) patients before and after HD and measured oxylipins in plasma by LC-MS/MS tandem mass spectrometry. Comparison between cytochrome P450 (CYP), lipoxygenase (LOX), and LOX/CYP ω/(ω-1)-hydroxylase metabolites levels from arterial and venous blood showed no arteriovenous differences before HD but revealed arteriovenous differences in several CYP metabolites immediately after HD. These changes were explained by metabolites in the venous blood stream of the upper limb. Decreased soluble epoxide hydrolase (sEH) activity contributed to the release and accumulation of the CYP metabolites. However, HD did not affect arteriovenous differences of the majority of LOX and LOX/CYP ω/(ω-1)-hydroxylase metabolites. The HD treatment itself causes changes in CYP epoxy metabolites that could have deleterious effects in the circulation.
More Related Videos
Related Concept Videos
Drug Biotransformation: Overview
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

